Anthracycline antineoplastic antibiotics such as doxorubicin or daunorubicin are widely used anticancer drugs. However, the administration of anthracyclines is connected with high risk of cardiotoxicity. Chronic anthracycline cardiotoxicity is characterized by dilated cardiomyopathy, with subsequent development of left ventricular contractile dysfunction and congestive heart failure. It is supposed that the complexation of anthracyclines with intracellular iron leads to the formation of reactive oxygen species, which causes serious tissue damage especially in myocardium.


The only clinically used drug preventing anthracycline cardiotoxicity is dexrazoxane (DXZ). It was argued, that its mechanism of action involves iron-chelating properties of ADR-925, main metabolite of DXZ. However, recent studies showed that the mechanism of action is more complex.



Our group deals with the synthesis of dexrazoxane analogues, with or without chelating properties. Analogues with modified linker between the piperazine-2,6-dione cycles, with modified piperazine-2,6-diones or with terminal succinimide cycles are studied.


Second main topic of our group lies in the synthesis of aroylhydrazones derived from salicylaldehyde isonicotinoyl hydrazone (SIH) as potential cardioprotective and antiproliferative agents.



© Charles University, Faculty of Pharmacy in Hradec Králové, Akademika Heyrovského 1203, 500 05 Hradec Králové, Czech Republic
Website information | Powered by Kentico